Metabolism and excretion of semaglutide, a GLP-1 analogue, in humans and nonclinical species
STEP 1 (14.9% weight loss at 68 weeks on semaglutide) and SURMOUNT-1 (20.9% on tirzepatide) data applies regardless of which provider you choose
However, global health authorities including the World Health Organization (WHO) and United States Food and Drug Administration (US FDA) have cautioned against the use of unregulated and compounded weight-loss injections, highlighting concerns over safety, quality, and lack of oversight
Those are empirical questions that require the kind of independent, well-powered testing that the field still largely lacks
Overall, Blue Cross Blue Shield provides coverage for certain prescription weight loss drugs, but members must meet specific criteria and may face restrictions and limitations on coverage